Literature DB >> 22998333

Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats.

Paulo V M Steagall1, Ludovic Pelligand, Tatiana Giordano, Christophe Auberger, John W Sear, Stelio P L Luna, Polly M Taylor.   

Abstract

OBJECTIVE: To describe simultaneous pharmacokinetics (PK) and thermal antinociception after intravenous (i.v.), intramuscular (i.m.) and subcutaneous (SC) buprenorphine in cats. STUDY
DESIGN: Randomized, prospective, blinded, three period crossover experiment. ANIMALS: Six healthy adult cats weighing 4.1±0.5 kg.
METHODS: Buprenorphine (0.02 mg kg(-1)) was administered i.v., i.m. or s.c.. Thermal threshold (TT) testing and blood collection were conducted simultaneously at baseline and at predetermined time points up to 24 hours after administration. Buprenorphine plasma concentrations were determined by liquid chromatography tandem mass spectrometry. TT was analyzed using anova (p<0.05). A pharmacokinetic-pharmacodynamic (PK-PD) model of the i.v. data was described using a model combining biophase equilibration and receptor association-dissociation kinetics.
RESULTS: TT increased above baseline from 15 to 480 minutes and at 30 and 60 minutes after i.v. and i.m. administration, respectively (p<0.05). Maximum increase in TT (mean±SD) was 9.3±4.9°C at 60 minutes (i.v.), 4.6±2.8°C at 45 minutes (i.m.) and 1.9±1.9°C at 60 minutes (s.c.). TT was significantly higher at 15, 60, 120 and 180 minutes, and at 15, 30, 45, 60 and 120 minutes after i.v. administration compared to i.m. and s.c., respectively. I.v. and i.m. buprenorphine concentration-time data decreased curvilinearly. S.c. PK could not be modeled due to erratic absorption and disposition. I.v. buprenorphine disposition was similar to published data. The PK-PD model showed an onset delay mainly attributable to slow biophase equilibration (t(1/2) k(e0)=47.4 minutes) and receptor binding (k(on)=0.011 mL ng(-1) minute(-1)). Persistence of thermal antinociception was due to slow receptor dissociation (t(1/2) k(off)=18.2 minutes). CONCLUSIONS AND CLINICAL RELEVANCE: I.v. and i.m. data followed classical disposition and elimination in most cats. Plasma concentrations after i.v. administration were associated with antinociceptive effect in a PK-PD model including negative hysteresis. At the doses administered, the i.v. route should be preferred over the i.m. and s.c. routes when buprenorphine is administered to cats.
© 2012 The Authors. Veterinary Anaesthesia and Analgesia. © 2012 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998333     DOI: 10.1111/j.1467-2995.2012.00779.x

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  8 in total

1.  Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).

Authors:  K R Kelly; B H Pypendop; K L Christe
Journal:  J Vet Pharmacol Ther       Date:  2014-03-25       Impact factor: 1.786

2.  Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum.

Authors:  Sarah J Phillips; Alison Oliveto; Michael J Mancino; Howard P Hendrickson
Journal:  Rapid Commun Mass Spectrom       Date:  2021-07-31       Impact factor: 2.586

Review 3.  A review of the studies using buprenorphine in cats.

Authors:  P V M Steagall; B P Monteiro-Steagall; P M Taylor
Journal:  J Vet Intern Med       Date:  2014-03-21       Impact factor: 3.333

4.  Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.

Authors:  Graeme M Doodnaught; Beatriz P Monteiro; Javier Benito; Daniel Edge; Francis Beaudry; Ludovic Pelligand; Paulo Steagall
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

5.  Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial.

Authors:  Paulo Vinicius Steagall; Hélène Louise Marcelle Ruel; Tomoyo Yasuda; Beatriz Paglerani Monteiro; Ryota Watanabe; Marina Cayetano Evangelista; Francis Beaudry
Journal:  BMC Vet Res       Date:  2020-05-24       Impact factor: 2.741

6.  Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (Callithrix jacchus).

Authors:  Niora J Fabian; David E Moody; Olga Averin; Wenfang B Fang; Morgan Jamiel; James G Fox; Monika A Burns; Jennifer L Haupt
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-07-19       Impact factor: 1.232

7.  The analgesic effects of buprenorphine (Vetergesic or Simbadol) in combination with carprofen in dogs undergoing ovariohysterectomy: a randomized, blinded, clinical trial.

Authors:  Ryota Watanabe; Beatriz P Monteiro; Marina C Evangelista; Amélie Castonguay; Daniel Edge; Paulo V Steagall
Journal:  BMC Vet Res       Date:  2018-10-05       Impact factor: 2.741

8.  The analgesic effects of buprenorphine (Vetergesic or Simbadol) in cats undergoing dental extractions: A randomized, blinded, clinical trial.

Authors:  Ryota Watanabe; Josée Marcoux; Marina C Evangelista; Yvan Dumais; Paulo V Steagall
Journal:  PLoS One       Date:  2020-03-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.